RESTORE: An RCT to Evaluate the Efficacy of the Revi System

Urinary Urge Incontinence Clinical Trial

Official title:

A Prospective Randomized Control Trial to Compare the Efficacy of the Revi System Therapy on Versus Off in Relieving Urinary Urge Incontinence Episodes.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06217328
• Other study ID #: G02-CLP-0019
• Status: Recruiting
• Phase: N/A
• Start date: February 24, 2024
• Est. completion date: May 31, 2027

Study information

• Verified date: June 2024
• Source: BlueWind Medical
• Contact: Roni Diaz, VP, Clinical & Regulatory Affairs
• Phone: 888-715-2080
• Email: roni.diaz[@]bluewindmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

Description:

Prospective, multi-center, open label, post market, randomized controlled trial

To demonstrate superiority of Revi System therapy vs. non active therapy in the treatment of UUI

Treatment Arm:

Device: Revi System Subjects will be implanted with a Revi System and activation of therapy will occur ~4 weeks post implantation and continue for the duration of the study.

Control Arm:

Device: Revi System - Delayed Activation Subjects will be implanted with a Revi System and activation of therapy will be delayed until 4 months post implantation. At this time the Revi System will be activated to begin therapy and will continue for the duration of the study.

Randomization in a 1:2 ratio into either the "control group" or the "treatment group" will be performed in blocks of 3 or 6 randomly, across the study population by a central randomization system. Randomization will be stratified by investigational site.

The study will consist of the following activities:

Visit 1 - Screening

• Potential subjects with UUI, who fulfil basic criteria will be informed of the study and will be invited to sign an informed consent form.

• Demographic information (age, race, height and weight, leg circumference), medical and surgical history and concomitant medication information will be collected.

• Study candidates will be asked to fill out various questionnaires

• Patients will be asked to complete a 3- consecutive day voiding diary.

• Urine sample will be collected, blood will be drawn and a full physical examination, including a PVR measurement and uroflow (in men), will be performed.

Visit 2 - Randomization & Implantation

• 5 ± 4 weeks after starting the diary, eligible subjects will be randomized to either the Treatment or Control (delayed activation) arms (2:1) and will undergo unilateral implantation with the BlueWind Revi System

• Collection of AE and concomitant medication will be performed

Treatment Arm:

Visit 3 - Activation

• After a recovery period of 4-weeks post implantation, subjects will attend the clinic to undergo physical examination and surgical wound check-up.

• Subjects will undergo parameter setting according to the individual patient sensations and will be trained on the use of the system.

Visits 4-11 - Treatment optimization and follow up

• Follow-up visits will be performed at 1, 2, 3, 6, 9, 12, and 24 months post system activation.

• A call visit will be performed at 18-months.

• All follow-up visits will require completion of a 3-day voiding diary by the patient before coming to the visit.

• During each clinic visit, stimulation parameters and level of treatment will be checked and adjusted as needed.

Control Arm:

• After a recovery period of 1-month post implantation, subjects will attend the clinic to undergo physical examination and surgical wound check-up.

Visit 4 - Activation

• After a recovery period of 4-weeks post implantation, subjects will attend the clinic to undergo physical examination and surgical wound check-up.

• Subjects will undergo parameter setting according to the individual patient sensations and will be trained on the use of the system.

Visits 5-12 - Treatment optimization and follow up

• Follow-up visits will be performed at 1, 2, 3, 6, 9, 12, and 24 months post system activation.

• A call visit will be performed at 18-months.

• All follow-up visits will require completion of a 3-day voiding diary by the patient before coming to the visit.

• During each clinic visit, stimulation parameters and level of treatment will be checked and adjusted as needed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: May 31, 2027
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent.

2. Subject is at least 21 years old, with no plans to become pregnant during the trial. If of child bearing potential and sexually active, negative pregnancy test and using acceptable contraception.

3. Subject has been diagnosed with UUI for at least 6 months.

4. Subject experiences a minimum of four (4) leaking episodes associated with urgency, with at least one episode per day for 2 days documented on a voiding diary for 3 consecutive days.

5. If used, subject should be on stable dose of antimuscarinics and/or beta-3 adrenergic agonists for at least 1 month prior to baseline and agree to remain on stable medication consumption until the 24-month follow-up visit.

6. If used, subject should be on a stable dose of tricyclic antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) for at least 3 months prior to baseline.

7. Subject agrees to attend all follow-up evaluations and is willing and capable to completely and accurately fill out voiding diaries and questionnaires and is willing to complete required exams and test

Exclusion Criteria:

1. Subject participation in a clinical investigation with an active treatment arm within the past 90 days.

2. Subject is a high surgical risk with multiple illnesses or active general infections that expose them to excessive bleeding or delayed or non-healing wounds. This includes patients who need anticoagulation therapy that cannot be temporarily stopped for the implantation procedure.

3. Subject with BMI >50.

4. Subject with any metal or other implant within 20cm distance of the area of BlueWind Revi implantation site.

5. Subject variation in diuretics consumption within the last 6 months.

6. Subject has received botulinum toxin injections for OAB within the past 12 months.

7. Subject with previous urinary incontinence surgery or prolapse surgery within the last 12 months.

8. Subject has had any spinal or genitourinary surgery within the last 6 months.

9. Subject had previous abdominoperineal resection of the rectum or radical hysterectomy (female)/ prostatectomy (male).

10. Subject with diagnosis of BPH with outflow/obstructive predominant symptoms.

11. Subject has skin, peripheral edema, orthopedic or neurologic anatomical limitations that preclude implantation or/and use of the device.

12. Subject with Alzheimer's, Parkinson, MS, stroke (CVI), neuropathy or injury resulting in neuropathy and/or suspected neurogenic bladder.

13. Subject has recurrent urinary tract infections (3 or more infections in the last 6 months), or presence of urinary fistula, or urinary tract obstruction such as cancer, urethral stricture or presence of urinary stone.

14. Subject with history of chemotherapy or pelvic radiotherapy that might have affected bladder control or caused neuropathies (i.e. peripheral neuropathy).

15. Male subject who have obstructive Benign Prostatic Hyperplasia (BPH) or other lower urinary tract obstructions.

16. Subject has open wounds or sores on the lower leg or foot or had previous, unhealed trauma in the implant area or has pitting edema (=2+) in the lower leg.

17. Subject has Venous or Arterial disease/insufficiency in the lower leg or Vasculitis or dermatologic condition in the lower leg or infections near the implantation site in the lower leg.

18. Subject has a documented history of allergic response to Platinum iridium, Titanium, Zirconia, Gold, Silicone or Parylene.

19. Subject has other active implantable electronic device/s regardless of whether stimulation is ON or OFF.

20. Subject has a life expectancy of less than 1 year.

Related Conditions & MeSH terms

• Urinary Incontinence, Urge
• Urinary Urge Incontinence

Intervention

Device:
• Revi System Treatment
The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
• Revi System - Delayed Activation
The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.

Locations

Country	Name	City	State
United States	Urology Partners of North Texas	Arlington	Texas
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Montefiore Medical Center	Bronx	New York
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	University of Texas Southwestern - Department of Urology	Dallas	Texas
United States	DHR Health Institute for Research and Development	Edinburg	Texas
United States	Adult and Pediatric Urology and Urogynecology	Omaha	Nebraska
United States	Chesapeake Urology	Owings Mills	Maryland
United States	Pasadena Urology	Pasadena	California
United States	Riverside Medical Clinic	Riverside	California
United States	Specialty Clinical Research of St. Louis, LLC	Saint Louis	Missouri
United States	University of Utah	Salt Lake City	Utah
United States	The Urology Place	San Antonio	Texas
United States	Willis-Knighton Clinical Research	Shreveport	Louisiana
United States	Sanford Female Pelvic Medicine & Reconstructive Surgery Clinic	Sioux Falls	South Dakota
United States	Florida Urology Partners	Tampa	Florida
United States	Arizona Urology Specialists	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
BlueWind Medical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Endpoint	Superiority of active Revi therapy over non-active therapy in the treatment of subjects with urinary urge incontinence based on a 3-day voiding diary	Month 4